<DOC>
	<DOC>NCT01933516</DOC>
	<brief_summary>The purpose of this study is to evaluate safety and pharmacokinetic of GP2013 in Japanese patients with CD20 positive low tumor burden indolent B-cell NHL under weekly dosing schedule.</brief_summary>
	<brief_title>GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patient with CD20 positive low tumor burden indolent Bcell non Hodgkin's lymphoma. Patient with at least one measurable lesion. Patient with ECOG performance status 0 or 1. Patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy. Patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy. Patient who has mAb therapy other than rituximab as prior line of therapy. Patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal). Patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>GP2013</keyword>
	<keyword>Japanese</keyword>
	<keyword>indolent B-cell non-Hodgkin's lymphoma</keyword>
	<keyword>biosimilar</keyword>
	<keyword>CD20</keyword>
	<keyword>GP13-101</keyword>
</DOC>